Biolegend, 356202, Purified anti-human VEGFR-3 (FLT-4) Antibody, 200μg

Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane, helix, and a cytoplasmic region with tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides that remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. Aberrant activation or expression of VEGFR and their ligands has been implicated in tumor angiogenesis, coronary artery disease, diabetic blindness, and other diseases.
200μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: VEGFR extracellular domain protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested IHC-P, IHC-F - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for relevant formats) include: immunohistochemistry staining of frozen or paraffin embedded sections1-3.
Application References(PubMed link indicates BioLegend citation): Jussila L, et al. 1998. Cancer Res. 58:1599. (IHC) Kilic N, et al. 2007. Blood 110:4223. (IHC) Folpe A, et al. 2000. Mod. Pathol. 13:180. (IHC)
Product Citations: Gallego-Delgado J, et al. 2016. J Clin Invest. 4016:126. PubMed Karlas A, et al. 2016. Nat Commun. 7:11320. PubMed Cooley L, et al. 2016. Sci Rep. 6: 25840. PubMed
RRID: AB_2561770 (BioLegend Cat. No. 356201)
Structure: Seven Ig-like domains in the extracellular domain, a single transmembrane helix, and a cytoplasmic region with tyrosine kinase activity
Distribution: Widely expressed in early embryogenesis endothelial cells, restrictly expressed on lymphatic endothelial cells in adults
Function: Mediates lymphangiogenesis in response to VEGF-C and VEGF-D, involved in cardiovascular development during embryogenesis
Ligand/Receptor: VEGF-C, VEGF-D
Biology Area: Cell Biology, Immunology, Signal Transduction
Molecular Family: Cytokine/Chemokine Receptors
Antigen References: 1. Tammela T, et al. 2008. Nature 454:656. 2. Partanen TA, et al. 2000. FASEB J. 14:2087. 3. Valtola R, et al. 1999. Am. J. Pathol. 154:1381. 4. Jussila L, et al. 1998. Cancer Res. 58:1599. 5. Galland F, et al. 1992. Genomics 13:475.
Gene ID: 2324
UniProt: View information about VEGFR-3 on UniProt.org
Clone: 9D9F9
Regulatory Status: RUO
Other Names: Receptor tyrosine Kinase VEGFR-3, VEGFR3, FLT4
Isotype: Mouse IgG1, κ